Blume-Jensen Peter's Form 4 filing
Acrivon Therapeutics, Inc. (ACRV) · filed Aug 27, 2026
- Accession no.
- 0000905148-26-003968
- Filed
- Aug 27, 2026, 4:14 PM ET
- Trade date
- Aug 25, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 0 derivative transactions. Open-market sales total $31.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Blume-Jensen PeterCIK 0001950499 | Director, Officer (President and CEO) |
| Masson KristinaCIK 0001950501 | Director, Officer (EVP - Business Operations) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Common Stock | SSaleDisposed | −14,036 | $2.21 | −$30,969.03 | 2,230,052 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.